ATRC — AtriCure, Inc.

AtriCure Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Worldwide revenue reached $154 million, a 13% increase year-over-year. U.S. revenue grew 14% to $125.6 million.
• Adjusted EBITDA: $27.3 million, up 78% from $15.4 million in Q2 2025.
• Net Income: $9 million compared to a net loss of $6.2 million in Q2 2025. Earnings per share were $0.18, up from a loss of $0.13.
• Gross Margin: Improved to 77.2%, up approximately 270 basis points year-over-year.
• Cash Position: Ended the quarter with $167.8 million in cash and investments, generating $22 million in cash during the quarter.

2. Strategic Updates and Business Highlights

• Product Performance:
  • Pain Management franchise grew 27% worldwide, driven by the cryoSPHERE MAX probe.
  • Open Ablation revenue increased 11%, supported by the EnCompass clamp.
  • Appendage Management grew 14%, with strong adoption of AtriClip FLEX-Mini and PRO-Mini devices.
• Clinical Trials:
  • The BoxX-NoAF trial has surpassed 50% enrollment, with expectations to complete by year-end 2026, targeting clinical data readouts in early 2027.
  • The LeAAPS trial continues with over 6,500 patients enrolled, focusing on stroke reduction benefits.
• Market Positioning: AtriCure views new entrants to the appendage management market as validation of growth potential, emphasizing their innovation and clinical evidence.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $602 million and $610 million, reflecting growth of approximately 12.5% to 14%.
• Adjusted EBITDA Guidance: Raised to approximately $85 million to $89 million for the year.
• Earnings Per Share Guidance: Projected between $0.05 to $0.13, with adjusted EPS between $0.24 to $0.32.
• Seasonality: Anticipates a slight sequential decline in Q3 revenue (1% to 2%) followed by a rebound in Q4.

4. Bad News, Challenges, or Points of Concern

• Minimally Invasive Ablation: This segment remains under pressure, with a decline in sales attributed to market focus on PFA catheters.
• International Markets: Some softness in key European markets, particularly the U.K. and Germany, with ongoing reimbursement challenges impacting performance.
• Competitive Pressures: New competitors entering the appendage management space could pose risks, although AtriCure believes their innovation and clinical data provide a strong defense.

5. Notable Q&A Insights

• Competitive Landscape: AtriCure's leadership emphasized their product superiority and ongoing innovation pipeline as key differentiators against new entrants.
• Pain Management Growth: The company noted robust growth in thoracic procedures and early traction in sternotomy and limb amputation markets, with expectations for continued expansion.
• Reimbursement Strategies: While the company is pursuing additional reimbursement for pain management products, current strong adoption is driven by positive clinical outcomes rather than existing reimbursement structures.
• Sales Force Expansion: AtriCure is actively hiring dedicated sales reps to support growth, particularly in the pain management segment, with a focus on leveraging existing accounts.

This summary encapsulates AtriCure's financial performance, strategic initiatives, and outlook while addressing challenges and competitive dynamics in the market.